Nalidixic Acid

證據等級: L5

預測適應症: 4 個

Nalidixic Acid: From Urinary Tract Infection to Conjunctivitis

One-Sentence Summary

Nalidixic acid is a first-generation quinolone antibiotic historically used to treat urinary tract infections caused by Gram-negative bacteria. The TxGNN model predicts it may be effective for Conjunctivitis, with 0 clinical trials and 6 publications currently in the evidence base — though none of the retrieved publications directly evaluates nalidixic acid as a treatment for conjunctivitis.

Quick Overview

Item	Content
Original Indication	No Philippines registration data available (historically: urinary tract infections)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.83%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, nalidixic acid is a first-generation quinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II), blocking DNA replication and exerting bactericidal activity. Its spectrum is directed primarily at Gram-negative organisms, including Escherichia coli, Proteus, and Klebsiella species.

The mechanistic argument for conjunctivitis rests on the observation that some conjunctivitis pathogens — notably Haemophilus influenzae and Moraxella catarrhalis — are Gram-negative and potentially susceptible. However, the most common bacterial conjunctivitis pathogens (Staphylococcus aureus, Streptococcus pneumoniae) are Gram-positive and largely outside nalidixic acid’s effective spectrum. This coverage gap substantially weakens the therapeutic rationale.

Critically, modern fluoroquinolones derived from nalidixic acid — specifically ciprofloxacin and ofloxacin ophthalmic formulations — have already been approved for bacterial conjunctivitis. They offer broader antibacterial coverage, superior ocular tissue penetration, and an established safety record in eye drops. The TxGNN high score most likely reflects network graph proximity rather than a clinically actionable new use.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34151142	2021	Case Report	Access Microbiology	Two cases of Tsukamurella pulmonis conjunctivitis in patients with nasolacrimal duct obstruction; nalidixic acid agar used as a microbiological culture medium only — not a treatment study
15824427	2005	Microbiological Characterization	Journal of Medical Microbiology	Characterization of Shigella boydii provisional serovar from diarrheal patients in Bangladesh; nalidixic acid mentioned in identification context — no conjunctivitis relevance
17446289	2007	Microbiological Characterization	Journal of Medical Microbiology	Novel Shigella dysenteriae serovar from Bangladesh; nalidixic acid referenced in phenotypic characterization only — no conjunctivitis relevance
9442487	1997	Molecular/Plasmid Analysis	Microbial Drug Resistance	Shigella dysenteriae type 1 plasmid study; nalidixic acid resistance documented as a plasmid-encoded trait — no conjunctivitis relevance
16914657	2006	Retrospective Microbiological Study	Journal of Medical Microbiology	>60% of Shigella sonnei isolates in Bangladesh were resistant to nalidixic acid — highlights widespread resistance, no conjunctivitis relevance
3206956	1988	Animal/Laboratory Study	Zhurnal Mikrobiologii	Yersinia virulence and invasiveness study using nalidixic acid-resistant mutants as experimental tools — no conjunctivitis relevance

⚠️ Important caveat: None of the 6 retrieved publications evaluates nalidixic acid as a therapeutic agent for conjunctivitis. The drug appears only as a microbiological laboratory reagent (selective culture medium ingredient or resistance marker). These papers provide no clinical support for this repurposing direction.

Philippines Market Information

Nalidixic acid is currently not registered in the Philippines. No product authorizations were found in the regulatory database.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence sits at L4 — mechanistic inference only — with no clinical trials and no literature directly supporting nalidixic acid as a treatment for conjunctivitis. The drug is not marketed in the Philippines, its safety profile in the local regulatory context is unverified, and modern fluoroquinolone ophthalmic preparations have already superseded any potential role in this indication, making clinical development essentially unjustifiable.

To proceed, the following would be needed:

Verified mechanism of action data (MOA) to confirm antibacterial spectrum against key conjunctivitis pathogens (S. aureus, S. pneumoniae, H. influenzae)
Philippines regulatory safety information — package insert warnings, contraindications, and DDI data
Ocular bioavailability and pharmacokinetic data for a topical ophthalmic formulation of nalidixic acid
A pre-clinical proof-of-concept study demonstrating in vitro activity against the primary conjunctivitis pathogen panel
A compelling differentiation argument over already-approved fluoroquinolone eye drops (ciprofloxacin, ofloxacin), without which investment in development is clinically unwarranted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.